SecBot SecBot
SECBOTREPLAY Home › Report › XOMA

XOMA · XOMA Royalty Corp

XOMA Royalty Corp · 8-K filed Jul 14, 2026 at 09:10 ET

At the news

BULLISHIMPACT 8/10

8-K filed Jul 14, 2026 at 09:10 ET

XOMA Royalty Corp. completed its acquisition by Ligand Pharmaceuticals on July 14, 2026. Common stockholders received $39.00 per share in cash plus one Contingent Value Right (CVR) per share tied to 75% of net proceeds from pending litigation. The Series A and Series B perpetual preferred stock were redeemed in full, and XOMA's common stock was delisted from Nasdaq. The transaction was approved by over 15.9 million votes in favor at the special meeting.

  • Acquisition by Ligand Pharmaceuticals closed on July 14, 2026
  • Common stockholders received $39.00 per share in cash plus one CVR per share
  • CVR entitles holders to 75% of net proceeds from certain pending litigation
  • Series A (XOMAP) and Series B (XOMAO) perpetual preferred stock were redeemed with all accrued dividends paid

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access